Emergent Biosolutions EBITDA Margin 2010-2023 | EBS

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Emergent Biosolutions (EBS) over the last 10 years. The current EBITDA margin for Emergent Biosolutions as of March 31, 2023 is .
Emergent Biosolutions EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2023-03-31 $0.98B $-0.18B -18.08%
2022-12-31 $1.12B $-0.03B -2.32%
2022-09-30 $1.51B $0.31B 20.48%
2022-06-30 $1.60B $0.32B 19.84%
2022-03-31 $1.76B $0.39B 22.41%
2021-12-31 $1.79B $0.48B 26.83%
2021-09-30 $1.65B $0.46B 27.89%
2021-06-30 $1.71B $0.55B 32.36%
2021-03-31 $1.71B $0.66B 38.63%
2020-12-31 $1.56B $0.55B 35.41%
2020-09-30 $1.33B $0.37B 27.68%
2020-06-30 $1.26B $0.38B 29.92%
2020-03-31 $1.11B $0.24B 22.02%
2019-12-31 $1.11B $0.23B 20.52%
2019-09-30 $1.02B $0.16B 15.54%
2019-06-30 $0.88B $0.09B 10.58%
2019-03-31 $0.86B $0.15B 17.52%
2018-12-31 $0.78B $0.15B 19.54%
2018-09-30 $0.71B $0.18B 25.92%
2018-06-30 $0.68B $0.21B 30.40%
2018-03-31 $0.56B $0.15B 25.98%
2017-12-31 $0.56B $0.17B 29.95%
2017-09-30 $0.52B $0.16B 31.21%
2017-06-30 $0.51B $0.15B 29.24%
2017-03-31 $0.50B $0.14B 27.63%
2016-12-31 $0.49B $0.14B 29.45%
2016-09-30 $0.48B $0.18B 37.24%
2016-06-30 $0.49B $0.20B 41.38%
2016-03-31 $0.53B $0.23B 42.99%
2015-12-31 $0.49B $0.18B 36.20%
2015-09-30 $0.45B $0.17B 36.89%
2015-06-30 $0.43B $0.13B 31.16%
2015-03-31 $0.41B $0.12B 28.99%
2014-12-31 $0.40B $0.12B 29.95%
2014-09-30 $0.40B $0.07B 16.50%
2014-06-30 $0.35B $0.05B 13.96%
2014-03-31 $0.32B $0.05B 16.10%
2013-12-31 $0.31B $0.06B 19.87%
2013-09-30 $0.31B $0.06B 19.74%
2013-06-30 $0.29B $0.05B 17.77%
2013-03-31 $0.28B $0.04B 15.64%
2012-12-31 $0.28B $0.04B 14.89%
2012-09-30 $0.30B $0.06B 21.02%
2012-06-30 $0.29B $0.05B 18.47%
2012-03-31 $0.31B $0.06B 20.98%
2011-12-31 $0.27B $0.04B 14.96%
2011-09-30 $0.27B $0.03B 11.15%
2011-06-30 $0.28B $0.05B 16.90%
2011-03-31 $0.26B $0.04B 16.28%
2010-12-31 $0.29B $0.08B 27.62%
2010-09-30 $0.24B $0.05B 19.83%
2010-06-30 $0.21B $0.02B 10.68%
2010-03-31 $0.22B $0.03B 13.82%
2009-12-31 $0.24B $0.05B 19.15%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.399B $1.121B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.614B 8.47
GSK (GSK) United Kingdom $70.187B 9.79
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.454B 22.07
Ginkgo Bioworks Holdings (DNA) United States $3.441B 0.00
Arcus Biosciences (RCUS) United States $1.502B 0.00
Biohaven (BHVN) United States $1.477B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.200B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00